.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Cipla
Merck
Fuji
Johnson and Johnson
Medtronic
Colorcon
Boehringer Ingelheim
Chinese Patent Office

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207322

« Back to Dashboard
NDA 207322 describes POLYMYXIN B SULFATE, which is a drug marketed by X Gen Pharms, West-ward Pharms Int, Gland Pharma Ltd, Paddock Llc, Xellia Pharms Aps, Fresenius Kabi Usa, and Aurobindo Pharma Ltd, and is included in seven NDAs. It is available from seven suppliers. Additional details are available on the POLYMYXIN B SULFATE profile page.

The generic ingredient in POLYMYXIN B SULFATE is polymyxin b sulfate. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.

Summary for NDA: 207322

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 207322

Ingredient-typePolymyxins

Suppliers and Packaging for NDA: 207322

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POLYMYXIN B SULFATE
polymyxin b sulfate
INJECTABLE;INJECTION 207322 ANDA Breckenridge Pharmaceutical, Inc. 51991-939 51991-939-17 10 VIAL, SINGLE-USE in 1 CARTON (51991-939-17) > 1 INJECTION, SOLUTION in 1 VIAL, SINGLE-USE (51991-939-99)
POLYMYXIN B SULFATE
polymyxin b sulfate
INJECTABLE;INJECTION 207322 ANDA Gland Pharma Limited 68083-174 68083-174-10 10 VIAL in 1 CARTON (68083-174-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (68083-174-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 500,000 UNITS BASE/VIAL
Approval Date:Apr 14, 2016TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Express Scripts
Chinese Patent Office
Baxter
US Army
Teva
Moodys
Cipla
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot